Psychosis and Antipsychotic Drugs: Overview

Psychosis manifests across multiple disorders including mood disorders, dementia, delirium with psychotic features, substance-induced psychosis, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Schizophrenia is the most prevalent, affecting approximately 1% of the global population. Understanding these distinctions helps clinicians tailor treatment approaches to underlying disease states.

First-generation antipsychotics block dopamine D2 receptors specifically. Second-generation antipsychotics antagonize both serotonin 5HT2A receptors and D2 receptors with lower affinity. This dual action in atypical agents often produces fewer extrapyramidal side effects compared to typical antipsychotics, making them preferred in many clinical scenarios.

Antipsychotics address positive symptoms like hallucinations, delusions, incoherent speech, and disorganized behavior by blocking dopamine receptors. They also aim to improve negative symptoms such as anhedonia, apathy, and alogia, as well as cognitive defects. The goal is comprehensive symptom management rather than targeting positive symptoms alone.

Poor adherence to antipsychotic medications significantly increases relapse risk in chronic psychotic disorders like schizophrenia and schizoaffective disorder. Continuous treatment reduces relapse rates and improves functional recovery. Monitoring adherence is essential because inconsistent medication use undermines therapeutic benefits and can lead to symptom recurrence.

Acute psychotic symptoms are managed with short-term antipsychotic therapy to reduce agitated behavior, hallucinations, and disorganized thoughts. Chronic psychotic illnesses like schizophrenia and schizoaffective disorder require long-term antipsychotic treatment to maintain symptom control and prevent relapse. Treatment duration depends on disorder chronicity and patient response.

Antipsychotic selection depends on the underlying disease state, clinical insight, potential drug-drug interactions, and patient sensitivity to adverse effects. For mania, atypical antipsychotics are typically preferred over typical agents due to lower extrapyramidal risk. Patients with major depressive disorder with psychotic features may require lower antipsychotic doses combined with antidepressants.

Clozapine is particularly effective in refractory schizophrenia but carries significant metabolic risks including weight gain and metabolic syndrome. Due to these serious adverse effects, it is used only when other antipsychotics have failed. Careful monitoring is necessary when clozapine is prescribed to manage its metabolic complications.